Different from other tumors, in ccRCC, non-synonymous mutations, neoantigens, insertions, or deletions caused by chromosomal structural changes and somatic CNVs were not associated with the efficacy of PD-1 inhibitors (Braun et al., 2020). Here, PDCD1 is linked to nonpapillary renal cell carcinoma.